PubMed Trending Research Digest — September 08, 2026

Automated digest · 98 articles · 15 research areas · September 08, 2026

Overview

Across this week’s set of articles, a dominant theme is precision and mechanism-driven care—spanning oncology, immunology, and cardiometabolic disease. Multiple studies use real-world data, biomarker stratification, and mechanistic pathways to refine treatment selection and toxicity management: for example, immune microenvironment predictors of daratumumab-lenalidomide resistance in multiple myeloma, organ-specific response dynamics in hepatocellular carcinoma treated with atezolizumab plus bevacizumab, and updated safety/monitoring characterizations for trastuzumab deruxtecan–related ILD across populations. In parallel, several cancer-focused mechanistic papers highlight how cellular and genomic context shapes resistance (e.g., ecDNA segregation under drug adaptation, tumor-resident bacteria driving epigenetic remodeling, and neutrophil ferroptosis resistance via S1P–TREM2), reinforcing that “what works” often depends on the state of the tumor ecosystem.

A second major theme is neuroimmune and systems biology approaches to chronic disease. Work on Alzheimer’s disease and related neurodegeneration emphasizes circuit-level and cell-state mechanisms (target engagement vs clinical benefit for tau therapies, hypoxia-linked PANoptosis pathways, and microglia metabolic reprogramming via nanomedicine). Meanwhile, gut–brain and neuro-immune frameworks appear in studies of inflammatory bowel disease neuropsychiatric manifestations, fecal microbiota transplantation for sepsis-associated encephalopathy, and early-life environmental programming of atopic dermatitis risk through fetal immune epigenetics. Together, these articles suggest that modulating immune metabolism, epigenetic regulation, and neuroinflammatory signaling may be as important as targeting single cytokines or single pathways.

Finally, the digest includes a strong translational/clinical implementation strand: guidelines and consensus statements (psoriasis, pulmonary hypertension, meniscus radial tears), pragmatic trials and comparative effectiveness studies (e.g., metoprolol in COPD without cardiovascular disease, early analgesia for ankle sprains, robotic surgery training and conversion risks), and pharmacovigilance analyses that inform safer prescribing (ceftriaxone–PPI QT/arrhythmia signals, ocular adverse events with minoxidil, BMI-related enfortumab vedotin toxicity). In cardiometabolic and vascular disease, incretin-based obesity therapies and body-composition interpretation (lean mass vs function) sit alongside device-based hypertension and RSV vaccination strategies—collectively pointing toward more individualized, evidence-calibrated interventions.

---

Neurodegeneration, Dementia & Disorders of Consciousness

Genome-wide association analyses highlight the neuronal contribution to multiple sclerosis susceptibility.

This multi-ancestry genome-wide association study analyzed 20,831 multiple sclerosis (MS) cases and 729,220 controls to identify susceptibility variants outside the major histocompatibility complex and to integrate single-cell blood/brain data for causal gene prioritization. It found 236 MS susceptibility variants (including four novel loci) and, after deriving a polygenic score and integrating single-cell datasets, highlighted inhibitory neurons as key contributors with 76 candidate causal genes. These findings strengthen the neuronal component of MS genetics and provide prioritized targets for mechanistic studies and potential therapeutic development beyond immune-cell loci.

Zeng L, Khan A, Fitzgerald KC et al. · Nature genetics · (2026) · View on PubMed ↗

Neural Circuit Mechanisms of Disorders of Consciousness and Potential Therapeutic Targets of Brain Stimulation.

This narrative review synthesized evidence on neural circuit mechanisms underlying disorders of consciousness (DoC) and mapped potential therapeutic targets for brain stimulation across integrated frameworks (ARAS, mesocircuit, and ICNs). A key update was that glutamatergic neurons in the pedunculopontine nucleus/laterodorsal tegmentum and parabrachial nucleus are highlighted as primary arousal drivers, with translation potentially relying on peripheral nerve stimulation. This is scientifically significant because it provides a structured target map to guide multi-target neuromodulation strategies for DoC.

Zhou Y, Cao T, Zhu S et al. · CNS neuroscience & therapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review.

This article combined a Mayo Clinic prospective cohort (Feb 2020–Jun 2026) with a systematic review to characterize clinical features and diagnostic tests in patients whose prion disease initially mimicked rapidly progressive Alzheimer disease (RPD). Among 204 RPD patients, five (2.5%) were identified as AD-prion disease mimics, and the study focused on which MRI/CSF and other clinical testing patterns best supported correct diagnosis. Clinically, recognizing these diagnostic pitfalls can prevent misclassification of prion disease as rapidly progressive Alzheimer disease and improve timely, appropriate management.

Elgenidi A, Shir D, Piura YD et al. · Journal of neurology · (2026) · View on PubMed ↗

From Target Engagement to Translational Disconnect: A Systematic Review and Narrative Synthesis of Direct Tau-Targeted Clinical Trials in Alzheimer’s Disease and Primary Tauopathies.

This systematic review and narrative synthesis evaluated direct tau-targeted clinical trials in Alzheimer’s disease and primary tauopathies to explain the translational disconnect between target engagement and clinical benefit. The key finding was that despite evidence of biological target engagement in many studies, clinical outcomes were inconsistent or limited, suggesting gaps between preclinical tau biology and trial endpoints/mechanisms. Scientifically, it highlights where translational strategy (e.g., biomarkers, trial design, and mechanistic alignment) may need improvement for tau-targeted therapies.

Yin L, Ren R, Leo C et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

HIF-1 exerts a double-edged sword regulatory role in hippocampal neuronal PANoptosis of Alzheimer’s disease through HK2/VDAC1/NLRP3 axis and RIPK3 signal.

This mechanistic preclinical study investigated how hypoxia-inducible factor-1 (HIF-1) regulates hippocampal neuronal PANoptosis in an Alzheimer’s disease mouse model via the HK2/VDAC1/NLRP3 axis and RIPK3 signaling. The key finding was that PANoptosis contributed to hippocampal neuronal loss and that HIF-1 exerted a “double-edged sword” regulatory effect on this death pathway through the specified molecular axis. These results are significant because they connect hypoxia signaling to integrated programmed cell death in AD and identify potential targets for modulating neurodegeneration.

Wang S, Luo L, Jiang X et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

The Role of overdose Folic Acid in Promoting Neuroinflammation, Oxidative Stress, and Apoptosis in SOD1-G93A Mice.

This preclinical study tested whether folic acid (FA) overdose affects neuroinflammation, oxidative stress, and apoptosis in the SOD1-G93A mouse model of amyotrophic lateral sclerosis (ALS). It found that low-dose FA prolonged lifespan, whereas medium and high doses shortened lifespan, with overdose FA increasing cerebellar inflammation (including elevated TNF-α) and promoting oxidative stress and apoptosis. The findings are significant because they suggest that FA supplementation may have dose-dependent neurotoxic effects in ALS models, informing safer translational use.

Zhu Y, Zhang Y, Yan T et al. · Free radical research · (2026) · View on PubMed ↗

Microstructural Brain Reserve Moderates the Associations Between 24-h Movement Behaviors and Cognition in Older Adults: Cross-Sectional Findings From the AGUEDA Trial.

This cross-sectional study in 89 cognitively unimpaired older adults from the AGUEDA trial (mean age 71.6 years) examined how 24-h movement behaviors measured by 9-day wrist-worn accelerometry (MVPA, LPA, sedentary behavior, and sleep) relate to cognition, and whether Alzheimer’s disease brain signatures (gray matter mean diffusivity and thickness/volume signatures) moderated these associations. The key finding was that microstructural brain reserve moderated the relationships between specific 24-h movement behaviors and cognitive performance. These results suggest that individual differences in Alzheimer’s-related brain microstructure may determine which movement behavior patterns are most protective for cognition in aging.

Fernandez-Gamez B, Solis-Urra P, Sanchez-Martinez J et al. · Scandinavian journal of medicine & science in sports · (2026) · View on PubMed ↗ · Free PDF ↗

Insights Into the Mechanisms of Biological Aging That Guide Translational and Clinical Research.

This editorial reviewed translational and clinical research directions informed by molecular mechanisms of biological aging, emphasizing “hallmarks of aging” such as genomic instability and related pathways. The key finding was that integrating these aging hallmarks can guide development of prevention and intervention strategies for age-associated diseases including dementia and sarcopenia, as well as rare progeroid disorders like Werner syndrome and ataxia telangiectasia. Scientifically, it frames how mechanistic aging biology can be leveraged to prioritize therapeutic targets and translational study designs.

Fang EF, Nilsen H, Scheibye-Knudsen M et al. · Aging medicine (Milton (N.S.W)) · (2026) · View on PubMed ↗ · Free PDF ↗

Microglia-targeted Panax notoginseng polysaccharide nanoparticles alleviate Alzheimer’s disease via AMPK-mTOR/HIF-1α-mediated immunometabolic reprogramming.

This Materials Today: Bio study developed microglia-targeted Panax notoginseng polysaccharide nanoparticles (KPBIT@NPs) to treat Alzheimer’s disease and tested their mechanism involving AMPK–mTOR/HIF-1α-mediated immunometabolic reprogramming. The key finding was that KPBIT@NPs alleviated AD pathology by reprogramming microglial immunometabolism through the AMPK–mTOR/HIF-1α axis, consistent with reducing the neuroinflammation–glycolysis feedback loop. This is significant because it provides a targeted nanomedicine approach that couples microglial metabolic control to therapeutic benefit in AD.

Zhang G, Kong L, Guo RB et al. · Materials today. Bio · (2026) · View on PubMed ↗ · Free PDF ↗

Connectomic mapping of pharyngeal and gut sensory circuits in adult Drosophila.

This iScience study used the Full Adult Fly Brain (FAFB) connectome to map pharyngeal and gut sensory circuits in adult Drosophila. The key finding was systematic identification and subtype classification of internal pharyngeal and gut sensory axons, followed by circuit mapping that revealed the major downstream brain regions they target. This is significant because it completes a systems-level wiring diagram for internal feeding-related sensory pathways, enabling mechanistic studies of how gut/pharynx signals shape behavior.

Giakoumas DS, Zhu JM, Jamal A et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Proteoform-Resolved Cross-Linking Reveals Environment-Dependent Structural Effects of α-Synuclein S129 Phosphorylation.

This study used quantitative cross-linking mass spectrometry to determine how wild-type alpha-synuclein (WT α-synuclein) and phosphorylated α-synuclein at serine 129 (pS129) respond to different chemical environments. The key finding is that α-synuclein S129 phosphorylation produces environment-dependent structural effects, meaning the phosphorylation-associated ensemble compaction seen in dilute solution does not necessarily generalize across biochemical contexts. This is significant for Parkinson’s disease biology because it links disease-relevant pS129 aggregation states to specific microenvironmental conditions that may shape toxicity and pathology.

Dollar AN, Kelley DW, Webb IK · Journal of the American Chemical Society · (2026) · View on PubMed ↗

Biomolecular Condensates Dictate the Folding Landscape of Protein Alpha-Helices.

This work investigated how biomolecular condensates alter the folding landscape of protein alpha-helices using atomistic simulations and comparative modeling against dilute solution and inert crowders. It finds that the helix–coil transition inside condensates differs markedly from behavior in dilute solution, indicating condensates reshape protein structure and dynamics beyond simple crowding effects. The significance is that it provides mechanistic insight into how cellular condensates could regulate protein folding and misfolding relevant to disease.

Hess N, Joseph JA · Journal of the American Chemical Society · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Immunotherapy, Targeted Therapy & Biomarkers

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.

In a first-in-human Phase 1/1b open-label dose-escalation study, the trispecific T-cell engager SAR443216 (HER2×CD3×CD28) was administered intravenously to participants with relapsed/refractory HER2-expressing solid tumors to assess safety, efficacy, pharmacokinetics, and pharmacodynamics. The study demonstrated the clinical evaluation of SAR443216 across dose levels (18–900 µg) using intraparticipant lead-in dosing, characterizing its T-cell activation biology via CD3 and CD28 co-engagement while targeting HER2+ tumor cells. This is clinically significant as it establishes early human tolerability/biologic activity for a next-generation HER2-directed immunotherapy designed to enhance antitumor T-cell responses.

Dumbrava EE, Oh DY, Ryu MH et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

This randomized, double-blind, placebo-controlled Phase 3 trial evaluated first-line chemotherapy plus pembrolizumab followed by maintenance pembrolizumab with or without the PARP inhibitor olaparib, with or without bevacizumab, in patients with advanced BRCA1/2 non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001). The key finding is the trial’s assessment of efficacy and safety strategies that extend pembrolizumab and incorporate olaparib maintenance despite BRCA non-mutation status. Scientifically and clinically, it tests whether combining immune checkpoint blockade with PARP inhibition can improve outcomes in a population lacking BRCA-mutant indications.

Vergote I, Cibula D, Powell M et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study.

This retrospective cohort study evaluated organ-specific antitumor dynamics of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) that had extrahepatic metastases. The key finding was that responses can differ between intrahepatic lesions and extrahepatic metastases, and organ-specific longitudinal assessment can capture discordance that RECIST binary criteria miss. This is significant because it supports more nuanced monitoring of immunotherapy–antiangiogenic treatment in advanced HCC to better reflect heterogeneous organ-level response.

Dejima A, Arai K, Chiba T et al. · Journal of gastrointestinal oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Incremental risk of high-grade adverse events with immune checkpoint inhibitors with or without poly(adenosine diphosphate-ribose) polymerase inhibitors in first-line treatment of advanced endometrial cancer: a systematic review and meta-analysis.

This systematic review and meta-analysis assessed the incremental risk of high-grade adverse events when immune checkpoint inhibitors (ICIs) are used with or without poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as first-line therapy added to platinum-based chemotherapy in advanced or recurrent endometrial cancer. Across randomized phase II/III trials, the pooled analyses quantified increased safety risks for specific high-grade toxicities depending on whether PARP inhibitors were combined with ICI-containing regimens. The findings are significant for treatment selection and toxicity monitoring in endometrial cancer patients considering chemo-immunotherapy ± PARP inhibitor strategies.

Gouveia MC, Obermair HM, Noronha MM et al. · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · (2026) · View on PubMed ↗

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

This multicentre, open-label phase 3 randomized trial studied whether adding neoadjuvant, concurrent, and adjuvant atezolizumab to stereotactic body radiation therapy (SBRT) improves outcomes versus SBRT alone in high-risk, early-stage, medically inoperable T1–T3N0M0 non-small-cell lung cancer (NSCLC) patients. The key finding was that the atezolizumab+SBRT strategy was superior to radiation alone for the trial’s primary/major clinical endpoints (as reported in the Lancet publication). Clinically, this supports incorporating atezolizumab with SBRT as a new standard-of-care option for selected high-risk resectable-ineligible early-stage NSCLC patients.

Daly ME, Simone CB, Redman MW et al. · Lancet (London, England) · (2026) · View on PubMed ↗

The changing therapeutic landscape of small-cell lung cancer.

This review studied the evolving therapeutic landscape of small-cell lung cancer (SCLC), emphasizing how advances in SCLC biology and cell-surface target discovery are translating into new treatment approaches. It reports that while SCLC initially responds to chemotherapy, recurrence is commonly refractory, and that identifying SCLC-enriched/differential cell-surface proteins has enabled multiple targeted therapies with early evidence of efficacy. The scientific significance is that ongoing biomarker and target refinement is reshaping SCLC treatment beyond cytotoxic chemotherapy toward more precise, mechanism-driven strategies.

Ross JS, Hockemeyer KG, Redin E et al. · Lancet (London, England) · (2026) · 2 citations · View on PubMed ↗

Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.

This review studied targeted therapies in advanced NSCLC, focusing on new biomarkers and treatment strategies across established driver alterations and emerging targets. It finds that biomarker-matched therapies for alterations including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK improve outcomes in molecularly defined subgroups, and it highlights emerging targets such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency. Clinically, it supports continued expansion of molecular testing and the use of next-generation tyrosine kinase inhibitors, bispecific antibodies, and antibody-drug conjugates to improve durability and intracranial control.

Hendriks LEL, Lin JJ, Tan DSW et al. · The Lancet. Respiratory medicine · (2026) · 1 citations · View on PubMed ↗

Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges.

This review studied emerging treatments and evolving challenges in early-stage NSCLC, including how immunotherapy and targeted therapy have changed the curative-intent paradigm. It reports that neoadjuvant or perioperative immunotherapy (and targeted approaches for actionable alterations) has defined a new standard-of-care framework for resectable early-stage disease, but introduces uncertainties around sequencing, duration, patient selection, and de-intensification/escalation. The clinical significance is that optimizing treatment selection and timing is now central to improving long-term outcomes while minimizing overtreatment.

Remon J, Cascone T, Saw SPL et al. · The Lancet. Respiratory medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.

This single-institution retrospective study evaluated an MRD-guided induction–intensification strategy using daratumumab-carfilzomib-based regimens followed by autologous stem cell transplantation (ASCT) in transplant-eligible patients with newly diagnosed multiple myeloma. Patients with persistent measurable residual disease (MRD) by multiparameter flow cytometry received treatment intensification—commonly daratumumab, carfilzomib, and dexamethasone—before ASCT, and the study reported high rates of MRD negativity prior to ASCT among evaluable patients. The clinical significance is that MRD status can be used to tailor intensification with anti-CD38–based therapy to improve depth of response before transplant.

Yokoyama D, Minakata D, Fujiwara SI et al. · Leukemia & lymphoma · (2026) · View on PubMed ↗

Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan.

This retrospective real-world study used Japan’s Medical Data Vision database (May 2020–April 2024) to assess first-line outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen-deprivation therapy (ADT) plus androgen receptor signaling inhibitors (ARSIs), focusing on PSA responses. The key finding was the cumulative incidence of achieving ≥90% PSA reduction (PSA90) during the first-line period, used to characterize treatment effectiveness and treatment duration in routine practice. These data support evidence-informed selection of ADT+ARSI first-line regimens for Japanese patients with mCSPC.

Kawai T, Kiyonaga F, Uno S et al. · Advances in therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Trastuzumab Deruxtecan-Associated Pneumonitis in Non-Breast Solid Tumors: A Retrospective Cohort Study.

This retrospective single-center cohort study evaluated adults with advanced non-breast solid tumors treated with trastuzumab deruxtecan (T-DXd) from January 2019 to May 2025, defining pneumonitis as new/worsening radiographic infiltrates not attributable to infection, progression, or other causes. The key finding was characterization of pneumonitis risk factors and clinical outcomes in this non-breast population receiving T-DXd in routine practice. The study is significant because it helps clinicians better anticipate and manage a serious toxicity that has been less well defined outside breast cancer cohorts.

Attia AM, Delgado JCT, Lecaros Zavalla AD et al. · Journal of immunotherapy and precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

This study analyzed 21 daratumumab-lenalidomide (DR) pre-treatment bone marrow samples from the IFM2017-03 phase 3 trial using single-cell and bulk multiomics to identify determinants of response. It found that an inflammatory bone marrow microenvironment associated with DR resistance includes upregulated NF-κB signaling genes in monocytes, increased proinflammatory ISG+ T cells, and reduced NK cell CD16 expression, consistent with impaired antibody-dependent cellular cytotoxicity. This is clinically important because it suggests immune microenvironment biomarkers and potential targets to improve DR responsiveness in multiple myeloma.

Cheng W, Gaggero S, Hasan Bou Issa L et al. · Biomarker research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Pulmonary Hypertension & Pulmonary Vascular Biology

Solving an enigma: the BMP-9/10 axis as a key regulator of pulmonary vascular resilience.

This review article examined the BMP-9/BMP-10 signaling axis and its receptors (ALK1, BMPRII, and endoglin) in pulmonary and systemic vascular biology. It proposes a bimodal model in which both deficiency and hyperactivation of BMP-9/10 disrupt vascular homeostasis, producing distinct pathogenic phenotypes such as obstructive pulmonary arterial remodeling. The significance lies in reframing BMP-9/10 as a context- and intensity-dependent regulator, guiding future biomarker and therapeutic strategies for vascular resilience versus disease.

Guignabert C, Humbert M · The European respiratory journal · (2026) · View on PubMed ↗ · Free PDF ↗

European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension.

This European Respiratory Society (ERS) clinical practice guideline update synthesized evidence for pulmonary arterial hypertension (PAH) treatment, emphasizing the activin signaling inhibitor sotatercept and the role of right heart catheterisation (RHC) during follow-up. The key finding is the guideline’s updated, evidence-based recommendations incorporating sotatercept and clarifying how RHC should be used to manage PAH patients longitudinally. Clinically, this standardizes contemporary PAH care and supports more pathway-targeted treatment decisions and improved hemodynamic monitoring.

Kovacs G, Zeder K, Humbert M et al. · The European respiratory journal · (2026) · View on PubMed ↗

Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort.

This retrospective multicentre Italian cohort study evaluated long-term safety and clinical predictors of selexipag therapy in systemic sclerosis–associated pulmonary arterial hypertension (SSc-PAH) patients diagnosed by right heart catheterization. The key finding was identification of survival, treatment persistence, and one-year mortality risk (COMPERA 2.0) outcomes and associated clinical predictors in 51 SSc-PAH patients treated with selexipag. These findings support evidence-based prognostication and patient selection for selexipag in SSc-PAH beyond trial settings.

Stano S, Iannone C, Campochiaro C et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗

Vascular smooth muscle cell-derived osteoprotegerin drives pulmonary arterial hypertension via AKT activation and is attenuated by monoclonal antibody therapy.

This mechanistic study investigated how vascular smooth muscle cell–derived osteoprotegerin (OPG; TNFRSF11B) drives pulmonary arterial hypertension (PAH) through AKT activation and how it can be attenuated by monoclonal antibody therapy. The key finding was that conditional deletion approaches identified vascular smooth muscle cells as a pathogenic source of OPG and that blocking OPG with a human monoclonal anti-OPG antibody reduces PAH severity in rodent models. This is significant because it supports OPG as a causal cell-derived mediator and provides a rationale for targeted anti-OPG therapeutic strategies in PAH.

Keles M, West LE, Arnold ND et al. · Cardiovascular research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Biology, Resistance & Genomic Mechanisms

S1P-TREM2 axis protects immunosuppressive neutrophils from ferroptosis to promote tumour progression in hepatocellular carcinoma.

This study investigated how the S1P–TREM2 axis enables tumor-associated neutrophils (TANs) in hepatocellular carcinoma (HCC) to resist ferroptosis and maintain immunosuppression. Using human HCC samples, multiple murine HCC models, transcriptomic/lipidomic profiling, genetic loss-of-function approaches, and therapeutic interventions, it identified S1P–TREM2 signaling as a protective program that preserves TAN survival under oxidative, lipid-rich tumor conditions. The significance is that targeting the S1P–TREM2 pathway could sensitize immunosuppressive neutrophils to ferroptosis and improve antitumor immunity in HCC.

Ma J, Wu T, Chen D et al. · Gut · (2026) · View on PubMed ↗ · Free PDF ↗

A microbial chromatin remodeler drives gastric cancer progression and immune evasion by reprogramming the host epigenome.

This mechanistic study identified Streptococcus anginosus (SA) as a tumor-resident oncobacterium that drives gastric cancer progression and immune evasion by reprogramming the host epigenome. It showed that SA extracellular vesicles deliver the bacterial chromatin remodeler saSNF2 into host cells, where saSNF2 uses its ATPase activity to partner with TEAD1 and promote BRG1/BRM-associated factor (BAF) complex assembly, upregulating the palmitoyltransferase ZDHHC11 to stabilize oncogenic transcriptional programs. The significance is that a transkingdom bacterial chromatin remodeling pathway can be targeted to overcome resistance to PD-1 blockade plus chemotherapy in gastric cancer.

Xie X, Wei Y, Zheng J et al. · Cell host & microbe · (2026) · View on PubMed ↗ · Free PDF ↗

The RNA helicase domain of NAT10 promotes the biogenesis of hypomodified ribosomes to enhance cancer cell proliferation.

The authors investigated how the RNA helicase domain of NAT10 contributes to ribosome biogenesis and cancer proliferation by combining PROTAC-mediated NAT10 degradation with deep mutational scanning, followed by biochemical assays, human cell line experiments, and female mouse xenografts. They found that the NAT10 helicase domain promotes proliferation and tumor growth through RNA-binding-dependent 18S rRNA binding, and that this proliferative effect is independent of NAT10’s RNA acetyltransferase activity. Scientifically, this pinpoints the NAT10 helicase function as a therapeutic vulnerability and supports domain-specific targeting strategies in NAT10-driven cancers.

Dalhat MH, Narayan S, Eleftheriou M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT.

This study developed INSIGHT, integrating cell sorting with mass spectrometry to perform quantitative phosphoproteomics and proteomics on discrete cell types from fixed tissues, and applied it to disseminating glioblastoma cells in patient-derived xenografts in mice. Disseminating tumor cells showed a proteome-wide state shift from proliferative to mesenchymal and neural progenitor-like programs, accompanied by rewired signaling networks and altered kinase activity. The approach and results enable in vivo, cell-type-resolved mapping of signaling in rare cancer states, informing mechanism-based targeting of disseminating glioblastoma.

Ahn R, D’Souza AD, Long L et al. · Nature communications · (2026) · View on PubMed ↗

Plasticity of extrachromosomal DNA segregation during drug adaptation.

Researchers studied how extrachromosomal DNA (ecDNA) segregation modes change during drug adaptation by combining single-cell DNA sequencing with cellular barcoding for clonal tracking under drug-free and drug-treated conditions. They found that segregation is not uniform across clones—different clones can exhibit distinct segregation behaviors even without drug pressure—indicating that drug resistance may arise from both selection of pre-existing clones and active reconfiguration under stress. This advances understanding of how ecDNA copy-number heterogeneity is generated and remodeled during therapy, which is central to predicting and countering resistance.

Shibata C, Miyata K, Akao M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

The nociceptor-CGRP-lactate axis in cancer immune escape: Linking neural signaling, immunometabolism, and immunotherapy resistance.

This article is a mechanistic review proposing the nociceptor–calcitonin gene-related peptide (CGRP)–lactate axis as a driver of cancer immune escape. The key synthesis is that neural signaling from nociceptors can reshape tumor immunometabolism (including lactate dynamics) to promote immunotherapy resistance and impaired immune surveillance. The review is significant because it frames a neural-immunometabolic pathway that could be therapeutically targeted to improve cancer immunotherapy responses.

Zhao PY, Wu K, Jin ZX et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

Twisting the End Game: How Telomere Chromatin Modifications Shape Telomere Maintenance.

This mechanistic review examined how telomere chromatin modifications influence telomere maintenance in proliferative versus differentiated cells and in cancer. It highlights that most cancers reactivate telomerase (~80%), while a subset uses break-induced replication (BIR)-mediated homologous recombination to activate alternative lengthening of telomeres (ALT). Understanding these telomere maintenance pathways and their chromatin regulation is clinically significant for developing targeted anti-cancer strategies against telomere biology.

Wang J, Su Y, Chen C et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Amyloid-Forming Amylin Secreted by the Pancreas Promotes Hypoxia-Inducible Factor Activation and Mitochondrial Alterations in Liver and Heart During Type 2 Diabetes Pathogenesis.

This mechanistic study investigated how amyloid-forming amylin (IAPP) secreted in type 2 diabetes activates hypoxia-inducible factor (HIF) signaling and alters mitochondria in liver and heart. The key finding was that amyloidogenic amylin promoted HIF activation and mitochondrial changes during T2D pathogenesis, linking systemic amyloid biology to hypoxic/metabolic dysfunction. This is significant because it identifies a potential pathway connecting IAPP aggregation to organ-specific metabolic injury in type 2 diabetes.

Knapton AE, Verma N, Kotiya D et al. · Comprehensive physiology · (2026) · View on PubMed ↗ · Free PDF ↗

Exercise-associated epigenetic remodeling and TCR repertoire dynamics in Lynch syndrome carriers.

This iScience study examined Lynch syndrome carriers undergoing a 52-week aerobic cycling intervention to determine how exercise reshapes DNA methylation and gene expression and alters the T cell receptor (TCR) repertoire. The key finding was compartment-specific DNA methylation changes, including innate immune activation in circulating cell-free DNA (cfDNA) and repression of oncogenic pathways in tissue, with ISL1 highlighted as an exercise-repressed epigenetic/transcriptional feature. This is significant because it links a non-pharmacologic cancer-prevention strategy (exercise) to measurable immuno-epigenetic mechanisms in a high-risk genetic population.

Wang J, Deng N, Martel-Martel A et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

---

Respiratory Disease, Vaccines & Airway Inflammation

Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.

The ORBEX trial studied whether the bacterial lysate OM-85 could prevent wheezing lower respiratory tract illness in preschool children at increased asthma risk, using a parallel-arm, double-blind, placebo-controlled randomized design. The key finding is the trial’s evaluation of OM-85 safety and efficacy for primary prevention in children aged 6–18 months with risk factors such as atopic dermatitis, parental asthma, or asthma in a blood sibling. This is significant because it tests a potential early-life intervention to reduce wheezing illnesses that predispose to asthma.

Morgan WJ, Mauger DT, Bacharier LB et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Nasal Epithelial Immune Signatures Are Associated With Age-Dependent Asthma Trajectories in Early Life.

This study analyzed nasal epithelial immune signatures in 265 children and young adults from the ALLIANCE cohort to link early-life wheeze biology with age-dependent asthma trajectories. Nasal transcriptomic cytokine-axis signatures—mapped to epithelial cells using single-cell RNA sequencing—were associated with distinct asthma outcomes across age and sensitization patterns. The results are important for identifying early biomarkers of asthma progression and for understanding how airway epithelial maturation programs shape disease trajectories.

Jakwerth CA, Illi S, Charles H et al. · Allergy · (2026) · View on PubMed ↗ · Free PDF ↗

RSV vaccine for preventing respiratory and cardiovascular hospitalizations in heart failure: a prespecified analysis of the extended DAN-RSV trial.

This prespecified analysis of the extended DAN-RSV trial evaluated whether an RSV vaccine could prevent respiratory and cardiovascular hospitalizations in patients with heart failure. The key finding (from the prespecified analysis) was the vaccine’s effect on hospitalization outcomes, extending assessment beyond respiratory endpoints to include cardiovascular events. This is clinically important because it informs RSV vaccination strategies in heart failure populations at high risk for both respiratory decompensation and cardiovascular complications.

Skaarup KG, Lassen MCH, Yafasov M et al. · European journal of heart failure · (2026) · View on PubMed ↗ · Free PDF ↗

Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease.

This multicenter, open-label, pragmatic phase 4 randomized trial enrolled 1695 COPD patients aged ≥40 years with sinus rhythm and no cardiovascular disease to test whether metoprolol 100 mg daily plus standard care reduces time to first COPD exacerbation, cardiovascular event, or death versus standard care alone. The key finding was that metoprolol did not meaningfully improve the primary composite outcome over 1 year compared with standard care. Clinically, the trial supports avoiding routine beta-blocker use with metoprolol solely for COPD outcomes in patients without cardiovascular disease.

Sundh J, Magnuson A, Kvarnström M et al. · NEJM evidence · (2026) · 1 citations · View on PubMed ↗

Risks of adverse respiratory outcomes in adults with cancer over the course of survivorship compared with cancer-free individuals: a matched cohort study using linked English electronic health records.

This matched cohort study used linked English electronic health records to compare adults with incident cancer (1999–2019) versus cancer-free individuals for risks of new or worsening chronic respiratory outcomes during survivorship. The key finding was that cancer survivors experienced higher risks of developing chronic respiratory conditions and/or exacerbations (including asthma, COPD, bronchiectasis, and interstitial lung disease) relative to matched controls. This is significant for survivorship care because it quantifies respiratory morbidity burden across common cancers and supports earlier monitoring and prevention strategies.

Andresen K, Carreira H, Forbes H et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Vagus Nerve Stimulation for Sleep Disorders: Emerging Evidence and Future Directions.

This 2026 review studied emerging evidence for vagus nerve stimulation (VNS) as a non-pharmacological treatment for multiple sleep disorders, including insomnia, central hypersomnia, restless legs syndrome, and sleep-related breathing disorders. The key finding was that both invasive VNS and non-invasive transcutaneous auricular VNS (taVNS) show promising clinical effects, with proposed mechanisms spanning neuromodulatory pathways relevant to sleep regulation. This is significant because it frames future clinical trials and mechanistic work to optimize VNS-based therapies for patients with limited options from medications.

Wang X, Sun Q, Zhang Y et al. · Nature and science of sleep · (2026) · View on PubMed ↗ · Free PDF ↗

---

Clinical Methods, Guidelines, Pharmacovigilance & Real-World Evidence

Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

This systematic analysis used the Global Burden of Disease Study 2023 comparative risk assessment framework to estimate second-hand smoke (SHS) exposure prevalence and attributable disease burden across 204 countries and territories from 1990–2023, stratified by age and sex. The key finding is a comprehensive quantification of SHS as a global risk factor over time and geography, including its contribution to multiple health outcomes. The significance is that it provides actionable, population-level estimates to guide public health policy and quantify the benefits of reducing SHS exposure.

The Lancet. Public health · (2026) · View on PubMed ↗ · Free PDF ↗

Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer.

This post hoc analysis studied independent ILD Adjudication Committee–adjudicated trastuzumab deruxtecan (T-DXd)-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer from all-patient post-marketing surveillance. The key finding was a comprehensive characterization of clinical and radiological features, including time to onset, interventions, and outcomes through 12 months after onset, based on committee-adjudicated cases. These real-world data improve risk recognition and management planning for T-DXd pneumonitis/ILD in Japanese oncology practice.

Fujiwara Y, Oikado K, Baba T et al. · The oncologist · (2026) · View on PubMed ↗ · Free PDF ↗

Comparison of analgesic treatments used for ankle sprains in the emergency department.

This prospective, randomized, double-blind emergency-department study compared early intravenous analgesia with paracetamol, ibuprofen, or dexketoprofen in patients with grade 1–2 ankle sprains. Early functional analgesia was assessed using pain monitoring and range-of-motion measurements, with the study designed to determine which drug improves pain and mobility after initial treatment. The findings are clinically relevant for selecting an evidence-based, rapidly acting analgesic strategy for ankle sprains in the ED to restore function sooner.

Sarcan E, Erdem AB, Yazla M et al. · Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · (2026) · View on PubMed ↗ · Free PDF ↗

Population-Based Prediction Equations for Appendicular Skeletal Muscle Mass: A Three-Phase Validation Study in 13 582 Asian Adults.

This three-phase validation study developed and validated population-based prediction equations for appendicular skeletal muscle mass (ASM) using anthropometric measures and common laboratory data (including serum creatinine) in 13,582 Asian adults. The key finding was that device-independent equations can estimate ASM in community settings, addressing limitations of DXA and bioelectrical impedance analysis. This is clinically significant because it enables scalable sarcopenia screening and diagnosis in Asian populations using readily available inputs.

Lai HY, Zhang S, Chen IT et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

Ocular Events Temporally Associated With Minoxidil: A Structured Review.

This structured review (PRISMA-guided) compiled published ocular adverse events temporally associated with topical or oral minoxidil exposure. The key finding was that ocular complications were reported across both topical minoxidil (most cases) and oral minoxidil, with a predominance of male patients and a mean age around the early 30s. This is significant for dermatology and prescribing practice because it highlights a potentially underrecognized ocular safety signal linked to minoxidil.

Akiska YM, Boginskaya O, Mumtaz A et al. · Journal of cutaneous medicine and surgery · (2026) · View on PubMed ↗ · Free PDF ↗

Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records.

This study investigated whether body mass index (BMI) is associated with enfortumab vedotin (EV)-related adverse events in Japanese patients using the JADER pharmacovigilance database (2004–2025) and single-center medical records, stratifying BMI as <22 vs. ≥22 kg/m². EV toxicity reporting odds ratios and event frequencies were analyzed and showed BMI-related differences in the risk of EV adverse events, particularly skin toxicity. These findings suggest BMI may be a clinically useful risk stratifier for EV toxicity in advanced urothelial carcinoma patients receiving antibody-drug conjugate therapy.

Kei M, Sato S, Yamaga R et al. · Biological & pharmaceutical bulletin · (2026) · View on PubMed ↗ · Free PDF ↗

QT Prolongation, Ventricular Arrhythmia, and Cardiac Arrest Signals During Ceftriaxone Co-therapy with Individual Proton Pump Inhibitors: A Multidatabase Study.

This two-stage real-world pharmacovigilance study analyzed combination safety signals for ceftriaxone co-therapy with individual proton pump inhibitors (PPIs) using the US FDA Adverse Event Reporting System (FAERS) and Canada Vigilance Adverse Reaction (CVAR) databases. The key finding was identification of drug-drug interaction signals for QVC events—QT prolongation, ventricular arrhythmia, and cardiac arrest—where combination signals exceeded component signals for specific PPI pairings. Clinically, these results suggest that not all PPIs may confer the same risk when used with ceftriaxone, informing safer co-prescribing and monitoring.

Chen Y, Gu Q, Zhao M et al. · Cardiovascular toxicology · (2026) · View on PubMed ↗ · Free PDF ↗

Delayed diagnosis and genetic testing in spinal muscular atrophy: a case series.

This case series described delayed diagnosis and genetic testing in spinal muscular atrophy (SMA), focusing on patients with deletions or disease-causing variants in the survival motor neuron 1 (SMN1) gene. The key finding was that both reported patients experienced long symptom durations before appropriate genetic diagnosis, despite SMA being genetically defined by SMN1 alterations. The series is significant because it highlights the need for earlier access to genetic testing to reduce diagnostic delays in SMA, especially in resource-limited settings.

Guo X, Luo Y, Li M et al. · Annals of medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Use of Vitamins and Supplements During Pregnancy and Their Association with Maternal and Birth Outcomes: A Prospective Cohort Study.

This prospective cohort study of 199 pregnant women in Jordan (enrolled from the second trimester to delivery) used structured interviews and medical record review to characterize prenatal vitamin/supplement types, adherence patterns, and their associations with maternal and birth outcomes. The key finding was that supplement use and adherence varied across pregnancy and were associated with differences in maternal and/or birth outcomes. Scientifically, the study highlights the importance of adherence to specific prenatal supplements as a modifiable factor in maternal-fetal health.

Alshdaifat RO, Taybeh EO, Al-Alami Z et al. · Patient preference and adherence · (2026) · View on PubMed ↗ · Free PDF ↗

Effect of High-Intensity Laser Acupuncture on Muscle Performance, Pain, and Quality of Life in Patients with Chronic Nonspecific Low Back Pain: A Randomized Placebo-Controlled Trial.

This randomized, prospective, double-blind, placebo-controlled trial enrolled 60 adults aged 20–40 years with chronic nonspecific low back pain to compare high-intensity laser acupuncture (HILA) plus physical therapy exercises versus sham placebo laser plus the same exercises over 4 weeks. The key finding was that HILA improved trunk muscular performance, reduced pain, and improved quality of life compared with sham treatment. Clinically, it supports HILA as an adjunct to exercise-based physical therapy for managing chronic nonspecific low back pain.

Elimy DA, Youssef ASA, Ragab MMM et al. · Journal of multidisciplinary healthcare · (2026) · View on PubMed ↗ · Free PDF ↗

Posterior Circulation Stroke After Subclavian Artery Thrombosis Following Low-Voltage Electrical Injury in an Active Woman With Previously Unrecognized Prothrombotic Risk Factors: A Case Report.

This case report described a 45-year-old woman who developed posterior circulation ischemic stroke after low-voltage electrical injury, with imaging showing a thrombus in the proximal right subclavian artery and multifocal posterior circulation infarcts. The key finding was that an extensive workup identified previously unrecognized prothrombotic risk factors as the likely contributor to arterial thrombosis and subsequent embolic stroke. The report is clinically significant because it highlights stroke risk after electrical injury and the need to evaluate for underlying hypercoagulability when thrombosis occurs.

MacLennan LP, Ashurst J, Balandin A · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Ribosome engineering enhances genetic code expansion in Saccharomyces cerevisiae.

This study in Saccharomyces cerevisiae investigated ribosome engineering by evolving 18S ribosomal DNA using a visual, plug-and-play screening platform to enhance genetic code expansion and noncanonical amino acid (ncAA) incorporation. The key finding was that the best-performing engineered strain (“ribo-hyper”) increased ncAA-dependent GFP production 2.9-fold versus the wild-type 18S rDNA strain and improved incorporation across multiple orthogonal aminoacyl-tRNA synthetase/tRNA pairs. This is significant because it provides an efficient eukaryotic ribosome-optimization strategy to expand the practical use of ncAAs in protein engineering.

Chen X, Shen W, Chen X et al. · Synthetic and systems biotechnology · (2027) · View on PubMed ↗ · Free PDF ↗

Epilepsy Is Part of the CNS Phenotype in Classic Infantile Pompe Disease.

This international study investigated whether epilepsy is part of the central nervous system (CNS) phenotype in patients with classic infantile Pompe disease who have hypertrophic cardiomyopathy, symptom onset before 6 months, and complete acid alpha-glucosidase (GAA) deficiency and/or two severe GAA variants. The key finding is that epilepsy should be considered part of the CNS phenotype in classic infantile Pompe disease, consistent with CNS involvement revealed after enzyme replacement therapy. This is scientifically and clinically important because it supports routine neurologic surveillance and may influence management strategies for patients receiving GAA enzyme replacement therapy.

Faraguna MC, Broomfield A, Gasperini S et al. · Neurology. Genetics · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Small-Molecule-Directed RNA Modification via Proximity-Driven Catalysis.

This study developed a small-molecule-directed, DMAP-catalyzed, proximity-driven method for site-selective RNA functionalization by appending a catalytic DMAP moiety to RNA-binding ligands. The key finding is that in the presence of azide-bearing acyl donors, 2′-OH groups on RNA are selectively acylated, enabling downstream functionalization steps (as indicated by subsequent azide-related chemistry). This is significant for RNA-targeted therapeutics and structure–function probing because it expands chemical RNA modification beyond prior constraints like guanine accessibility or multi-strand helper systems.

Chen S, Kha TK, Zhao Y et al. · Journal of the American Chemical Society · (2026) · View on PubMed ↗ · Free PDF ↗

---

Wound Healing, Biomaterials & Regenerative Medicine

Identification of the tendon/ligament stem cell in mice and humans.

This study used mouse and human tissue analyses to identify the tendon/ligament stem cell (TLSC) responsible for tendon/ligament maintenance and for lineage contributions relevant to ligamentum flavum hypertrophy and lumbar spinal stenosis (LSS). It identified TLSCs as Lin-Thy1.2-Sca-1-CD73+CD140α- cells with self-renewal capacity and demonstrated, via in vivo somatic-variant-based lineage tracing, that TLSCs sit at the apex of the tenocyte differentiation hierarchy; LSS induction triggered calcium signaling-dependent, cell-intrinsic reprogramming of TLSCs. The significance is that TLSCs provide a definable cellular target for developing disease-modifying therapies for LSS.

Hu L, Sun J, Morse KW et al. · Cell · (2026) · View on PubMed ↗

Matrix Stiffness Orchestrates Mesenchymal Stem Cell Lineage Commitment Toward Osteogenesis and Adipogenesis Through the PIEZO1/SP1/STC2 Axis.

This study used single-cell RNA sequencing reanalysis of the public dataset GSE166824 plus mouse MSC functional assays and in vivo bone defect models to define how matrix stiffness regulates mesenchymal stem cell (MSC) fate via the PIEZO1/SP1/STC2 axis. The key finding was that stiff extracellular matrices activate the mechanosensitive channel PIEZO1, promoting osteogenesis while inhibiting adipogenesis through downstream PIEZO1/SP1/STC2 signaling. This is significant for bone regenerative biology because it identifies a mechanotransduction pathway that could be targeted to bias MSC differentiation toward osteogenesis.

Zhang S, Li S, Chen W et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Fecal microbiota transplantation alleviates sepsis-associated encephalopathy by reshaping gut microbiota and metabolism.

This preclinical study investigated whether fecal microbiota transplantation (FMT) alleviates sepsis-associated encephalopathy (SAE) in rats, focusing on gut microbiota remodeling and tryptophan metabolism. Using cecal ligation and puncture to induce SAE, the authors found that FMT improved cognitive/emotional performance and altered gut metabolite profiles measured by untargeted metabolomics alongside 16S rDNA sequencing, consistent with a gut–microbiota–brain axis effect. The findings suggest FMT as a mechanistically informed, microbiome-targeted therapeutic strategy for SAE involving dysregulated tryptophan pathways.

Guan L, Yu M, Lin Y et al. · Microbial pathogenesis · (2026) · View on PubMed ↗

Molecular design and delivery of extracellular and membrane protein degradation chimeras.

This review studied molecular design and delivery principles for extracellular and membrane protein degradation chimeras as a strategy to expand beyond ubiquitin-proteasome–centric intracellular degradation. It reports that meTPD (membrane and extracellular targeted protein degradation) works by coupling target recognition to degradation-competent uptake and intracellular trafficking to lysosomal routes, rather than relying on a single receptor/platform. Scientifically, it consolidates trafficking- and degradation-route–based designs (e.g., lysosome-targeting receptor-dependent systems and transmembrane E3 ligase recruitment) to guide development of next-generation targeted degraders for extracellular/membrane targets.

Lin S, Zhou H, Qiu J et al. · Advanced drug delivery reviews · (2026) · View on PubMed ↗

High-frequency high-intensity focused ultrasound (HF-HIFU) for ablation of benign, premalignant, and malignant cutaneous lesions: a systematic review.

This systematic review evaluated high-frequency high-intensity focused ultrasound (HF-HIFU) as a non-invasive thermal ablation technique for benign, premalignant, and malignant cutaneous lesions across eligible clinical studies. The review found that evidence is fragmented by indication and study design, limiting firm conclusions about comparative effectiveness and optimal protocols. HF-HIFU is a promising, depth-controlled dermatologic ablation approach, but higher-quality prospective trials are needed to define its clinical role for specific lesion types.

Aguglia R, Niederegger T, Satea M et al. · European journal of dermatology : EJD · (2026) · View on PubMed ↗

An adhesive hydrogel enabling spatiotemporal delivery of umbilical cord exosomes for scarless skin regeneration through immunomodulation and ECM remodeling.

This preclinical study developed an adhesive dual-network hydrogel (GelMA-PBA/HANB/HepMA) that enables spatiotemporal delivery of umbilical cord exosomes for scarless skin regeneration. The key finding was that the hydrogel’s immunomodulation (macrophage polarization toward a pro-healing phenotype) and extracellular matrix (ECM) remodeling promoted regenerative healing while reducing scarring. Scientifically, it demonstrates a biomaterial strategy that couples controlled exosome delivery with a pro-regenerative immune/ECM microenvironment for full-thickness skin repair.

Zhang Y, Xie J, Li J et al. · Bioactive materials · (2027) · View on PubMed ↗ · Free PDF ↗

Targeting the neuro-immune-skin axis: Advanced functional biomaterials for intelligent wound management and regeneration.

This 2026 review studied how the neuro-immune-skin axis—bidirectional signaling between peripheral neurons and cutaneous immune cells via neuropeptides, neurotransmitters, and cytokines—can be leveraged in advanced functional biomaterials for wound management and regeneration. The key finding was that integrating neuroimmune signaling with responsive wound biomaterial design enables dressings that can dynamically react to changing wound microenvironments rather than acting as static coverings. This is significant because it provides a mechanistic blueprint for next-generation “intelligent” wound therapies targeting inflammation and healing coordination.

Li X, Ding Z, Huang Z et al. · Materials today. Bio · (2026) · View on PubMed ↗ · Free PDF ↗

---

Musculoskeletal Surgery, Rehabilitation & Orthopedics

Robotic surgery across surgical specialties: an Italian survey on implementation, training, and satisfaction levels among trainees and young attendings: on behalf of the Italian Multispecialty Society of Young Surgeons (SPIGC).

This nationwide Italian survey studied implementation, training exposure, and satisfaction with robotic surgery across trainees and young attendings in multiple surgical specialties using a modified-Delphi consensus and a multicentre questionnaire. The key finding was the reported status of robotic training programs and levels of satisfaction among residents/fellows/PhD students/young attendings across 10 specialties. The results highlight gaps and inform standardization of robotic training curricula across European surgical institutions.

Del Giudice F, Santarelli V, Fiori G et al. · Updates in surgery · (2026) · View on PubMed ↗ · Free PDF ↗

Staying minimally invasive: robotic versus laparoscopic colorectal cancer surgery in a propensity-weighted Italian multicentre cohort.

This propensity-weighted secondary post hoc analysis of the retrospective ATOCCS cohort studied conversion to open surgery after intended robotic versus laparoscopic colorectal cancer resection in Italian centres performing both approaches during 2022–2024. The key finding was the comparative, adjusted conversion risk between robotic and laparoscopic surgery using propensity-score overlap weighting with centre indicators and centre-clustered models. This supports evidence on whether robotic “staying minimally invasive” reduces conversion in routine multicentre colorectal cancer surgery.

Giordano A, Marano L, Lamacchia G et al. · Journal of robotic surgery · (2026) · View on PubMed ↗

Cortical hypertrophies in cementless short stem total hip arthroplasty in young patients under 60 years and elderly patients over 75 years-analysis of outcome and risk factors for cortical hypertrophies.

This retrospective analysis studied cortical hypertrophies on imaging after cementless short-stem total hip arthroplasty (THA) in two age groups: patients under 60 years and elderly patients over 75 years. The key finding was an assessment of differences in clinical outcomes (including Harris Hip Scores) and risk factors for cortical hypertrophy presence across these age strata. Clinically, it clarifies whether cortical hypertrophy after short-stem cementless THA has different prognostic relevance by patient age.

Schwarz PM, Stützle S, Stadler C et al. · Archives of orthopaedic and trauma surgery · (2026) · View on PubMed ↗ · Free PDF ↗

Impact of hematologic disorders on decline in hemoglobin levels after total hip arthroplasty.

This single-center matched retrospective cohort study investigated how hematologic disorders affect postoperative hemoglobin decline and blood loss after unilateral total hip arthroplasty for osteonecrosis of the femoral head. The key finding was the comparison of postoperative red blood cell count and hemoglobin-related outcomes between a hematologic-disorders group and matched controls. Scientifically and clinically, it identifies whether baseline hematologic disease increases perioperative anemia risk after THA, informing preoperative risk stratification and management.

Jiang M, He Z, Zhang Y et al. · The Journal of international medical research · (2026) · View on PubMed ↗ · Free PDF ↗

An International Delphi Consensus on Meniscus Radial Tears: From Diagnosis to Management and Rehabilitation.

This international Delphi consensus study aimed to establish expert agreement statements on diagnosis, nonoperative management, surgical indications/techniques, and rehabilitation outcomes for meniscus radial tears (MRT). The key finding was that a panel of 45 international orthopaedic surgeons reached consensus using predefined Likert-scale thresholds (≥80% agreement and <20% disagreement) to retain or revise statements. Clinically, the resulting standardized guidance supports consistent decision-making and rehabilitation planning for MRT across sports medicine practices.

Dzidzishvili L, Pace JL, Flanigan DC et al. · Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · (2026) · View on PubMed ↗

---

Autoimmune & Inflammatory Diseases (Mechanisms & Therapeutics)

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update.

These Saudi clinical practice guidelines studied evidence-based management recommendations for moderate-to-severe plaque psoriasis in adults and pediatric patients in the Kingdom of Saudi Arabia (KSA). The key finding was the development of updated guidance using the GRADE methodology and a systematic review of PubMed/EMBASE/Cochrane evidence from 2020–2026, structured around 31 PICO questions. This provides locally tailored, standardized treatment recommendations to improve psoriasis care in KSA.

Fatani MI, Binamer Y, Alessa D et al. · The Journal of dermatological treatment · (2026) · View on PubMed ↗ · Free PDF ↗

Dynamic chromatin tethering of MDC1 regulates genome stability.

This mechanistic study examined how dynamic chromatin tethering by Mediator of DNA Damage Checkpoint 1 (MDC1) regulates genome stability during homologous recombination (HR). The key finding was that the PST repeat region of MDC1 is a multivalent nucleosome-binding domain that tethers chromatin, enabling efficient RAD51 loading in interphase and supporting HR, with PST-mediated binding also contributing in mitosis. These results define a specific MDC1 domain-based mechanism linking chromatin tethering to HR efficiency and genome stability.

Heyza JR, Mikhova M, Phillips C et al. · Nucleic acids research · (2026) · View on PubMed ↗ · Free PDF ↗

Human Monocytic Models Reveal Genotype-Dependent Inflammatory Programs in VEXAS Syndrome.

This study investigated genotype-dependent inflammatory programs in VEXAS syndrome using human monocytic models carrying major somatic UBA1 mutations (p.Met41Val, p.Met41Thr, p.Met41Leu). The key finding was that deep phenotyping with whole-blood RNA-seq and single-cell RNA-seq, together with transcriptomic and functional analyses in genotype-specific monocytic cell lines, revealed distinct inflammatory programs by UBA1 genotype. This supports genotype-informed therapeutic target discovery for VEXAS syndrome.

Higashitani K, Ban T, Kirino Y et al. · Arthritis & rheumatology (Hoboken, N.J.) · (2026) · View on PubMed ↗ · Free PDF ↗

Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis.

This real-world study evaluated clinical outcomes and peripheral immune modulation in 81 patients with moderate-to-severe atopic dermatitis treated with the IL-13 monoclonal antibody tralokinumab, with PBMC immunophenotyping in a subset (n=25) using multiparameter flow cytometry. Tralokinumab improved standard disease measures (oScorad, IGA, BSA, DLQI, and pruritus-VAS) over 3–12 months and was associated with systemic shifts in T-cell subsets including markers such as CLA and OX40, along with changes in cytokines (IL-4, IL-13, IL-17A, IL-10, IFNγ). These findings support that IL-13 blockade with tralokinumab not only improves skin disease in routine care but also measurably modulates circulating immune pathways relevant to atopic dermatitis.

Almaci M, Globig P, Redhu D et al. · Clinical and translational allergy · (2026) · View on PubMed ↗ · Free PDF ↗

Prenatal PM2.5 exposure drives epigenetic reprogramming of fetal macrophages linked to atopic dermatitis.

This study examined whether first-trimester prenatal PM2.5 exposure programs fetal immune cells toward atopic dermatitis risk by integrating multi-omics analyses including single-cell approaches in human samples. PM2.5 exposure was linked to increased early-childhood AD risk and to hypomethylation of FCER1G in fetal macrophages, driving sustained FCER1G overexpression. The work identifies a specific epigenetic mechanism (FCER1G hypomethylation) in fetal macrophages that may mediate how early air pollution exposure predisposes to atopic dermatitis.

Yang DY, Yang SI, Park YJ et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Macrophages tune NK cell IFNγ production through direct lipid transfer.

This work investigated how macrophages regulate NK cell function by directly transferring lipids, using co-culture and in vivo models to measure NK cell mTORC1 activity and IFNγ production. Lipopolysaccharide-stimulated macrophages induced lipid accumulation in NK cells, suppressing mTORC1 signaling and reducing IFNγ output, with lipid droplets in NK cells traced to fatty acids synthesized within macrophages. The study identifies a direct macrophage-to-NK metabolic communication axis that can tune innate immune effector function and may be relevant to inflammatory disease control.

Keane C, Mayock S, Corkish C et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line.

This in vitro study examined the roles of protein kinase C delta (PKCδ) signaling and monocarboxylate transporter 4 (MCT4) in statin-induced cytotoxicity using a rhabdomyosarcoma-derived cell line (RD cells). The key finding was that statin cytotoxicity involved PKCδ-dependent regulation of MCT4, linking lactate transport and intracellular acidification to cell death mechanisms. Scientifically, it identifies a mechanistic pathway (PKCδ–MCT4) that could inform strategies to mitigate statin-associated muscle toxicity such as rhabdomyolysis.

Okamoto K, Matsui T, Kikutani Y et al. · Biological & pharmaceutical bulletin · (2026) · View on PubMed ↗ · Free PDF ↗

Aire Deficiency Disrupts Thymic Architecture but Preserves TCRVβ Repertoire Diversity While Altering Thymic Output.

This study used a murine Aire-deficient model created by CRISPR-Cas9 deletion in exon 6 (SAND domain) to determine how Aire loss affects thymic architecture, T cell receptor (TCR) repertoire diversity, and thymic output. The key findings were that Aire deficiency caused marked disorganization of the thymic medulla and focal alopecia while preserving TCRVβ repertoire diversity, with altered thymic output. Immunologically, it clarifies how Aire controls central tolerance and thymic structure/function without necessarily collapsing early TCR diversity.

Matos AA, Araujo IL, Munuera MD et al. · Immunology letters · (2026) · View on PubMed ↗ · Free PDF ↗

T cell-derived CCL5 drives macrophage immunometabolic remodeling in chronic prostatitis via the CCR5-ERK-PKM2/HIF-1α axis.

This study investigated how T cell-derived CCL5 drives macrophage immunometabolic remodeling in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) via the CCR5–ERK–PKM2/HIF-1α axis. Using integrated mouse autoimmune prostatitis models, chronically inflamed human prostate tissue, and single-cell transcriptomics/spatial profiling, the authors identified glycolytic, HIF-1α–activated inflammatory macrophages enriched in diseased niches and showed that CCL5 acts on CCR5+ macrophages to license M1-like polarization through ERK signaling and PKM2/HIF-1α–linked metabolic reprogramming. Scientifically and clinically, it implicates the CCL5/CCR5–ERK–PKM2/HIF-1α pathway as a mechanistic target for controlling sterile prostatic inflammation and pain.

Liu X, Li B, Dou X et al. · Redox biology · (2026) · View on PubMed ↗ · Free PDF ↗

Fatty Acid Metabolic Reprogramming in Rheumatoid Arthritis: Integrating Inflammation, Resolution Failure, and Joint Destruction.

This review article synthesized evidence on rheumatoid arthritis (RA) pathogenesis focusing on fatty acid metabolic reprogramming and how it links persistent inflammation, failure of inflammation resolution, and joint destruction. The key finding was that altered fatty acid/lipid metabolism can actively drive immune-cell dysfunction and contribute to synovitis persistence and structural damage beyond classical cytokine and autoantibody mechanisms. This provides a mechanistic rationale for targeting lipid metabolic pathways to improve RA resolution and prevent joint destruction.

Li T, Li G, Yang Y et al. · Journal of inflammation research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Renal Disease & Urologic Conditions

Clinical Significance of Increased Degree of Hematuria in Patients affected by IgA Nephropathy.

This retrospective single-center study evaluated the clinical significance of increased hematuria degree in 696 patients with primary IgA nephropathy (IgAN) with persistent hematuria. The key finding was that patients with a time-averaged hematuria ratio increase (Δ u-RBC count ≥1) were compared with matched patients with decreased hematuria using survival analyses (e.g., Kaplan–Meier) to determine prognostic impact. Clinically, it clarifies whether worsening hematuria burden predicts adverse outcomes in IgAN and can guide risk stratification.

Huang Z, Ma J, Bian X · Journal of nephrology · (2026) · View on PubMed ↗

Subclinical liver disease and incident cardiovascular events.

This prospective cohort study evaluated whether non-invasive markers of subclinical liver disease—fatty liver index (FLI) for steatosis, fibrosis-4 index (FIB-4) for fibrosis, and albumin-bilirubin (ALBI) score for functional decline—predict incident cardiovascular disease (CVD) events in 318,308 participants without baseline clinical liver disease or CVD. It found that hepatic steatosis, fibrosis, and functional decline were independently associated with major incident CVD, with evidence for synergistic risk across these dimensions. Clinically, the results support using routine non-invasive liver biomarkers to refine cardiovascular risk prediction beyond traditional factors.

Li L, Wu L, Hu Z et al. · European heart journal · (2026) · View on PubMed ↗

Pan-PPAR agonists: emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease.

This review examined emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease (MASLD) with a focus on pan-PPAR agonists and their mechanistic rationale in MASLD pathobiology. It highlights PPAR-driven regulation of lipid metabolism, insulin sensitivity, inflammation, and oxidative stress as a unifying target framework, positioning pan-PPAR agonism as a potentially broader approach than single-PPAR targeting. Clinically, this supports continued development and stratification of PPAR-based drugs to address the progressive MASLD spectrum from steatosis to steatohepatitis and cancer risk.

Guo M, Wu Q, Deng CH et al. · Metabolism: clinical and experimental · (2026) · View on PubMed ↗

Circadian and behavioral timing in MASLD: a systematic review of human observational studies.

This systematic review studied associations between circadian and behavioral timing exposures and metabolic dysfunction–associated steatotic liver disease (MASLD), including steatosis, fibrosis, cirrhosis, and quantitative liver-fat outcomes, across human observational studies. The key finding was a synthesized narrative pattern linking timing-related exposures (sleep/activity/light/food timing) to MASLD risk and severity, while emphasizing heterogeneity typical of observational timing research. This is significant because it identifies potentially modifiable behavioral timing targets for future interventional studies aimed at preventing or slowing MASLD progression.

Subramanian A, Raja Ali RA, Dawe GS et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimmunology & Immune Cell Crosstalk (Gut/Brain/Neuro-immune)

Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.

This case report described a 42-year-old woman who developed post–COVID-19 mRNA vaccination dysautonomia (vasovagal syncope and postural orthostatic tachycardia syndrome features) and improved after treatment with the GLP-1 receptor agonist semaglutide. The key finding was a substantial reduction in symptom burden, including a 44% decrease in COMPASS-31 score after semaglutide. The report is significant as it suggests a potential therapeutic role for GLP-1 receptor agonism in post-vaccination dysautonomia, warranting further study.

Blitshteyn S, Schofield JR, Haire N et al. · Immunopharmacology and immunotoxicology · (2026) · View on PubMed ↗

Targeting m6A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo.

Researchers developed siMETTL3-hNVs, an engineered epigenetic nanomodulator that delivers siRNA against the m6A writer METTL3 using microglia-derived nanovesicles (NVs) plus liposomes, to test effects on neuroinflammation in vitro and in vivo. Targeting METTL3 reduced neuroinflammatory responses and enabled inflamed-brain delivery across the blood–brain barrier via CCR2–CCL2 chemotaxis and caveolae-mediated transcytosis. This provides a mechanistically grounded therapeutic strategy for neuroinflammation by combining m6A epigenetic silencing with BBB-penetrant nanovesicle delivery.

Xu L, Pan Y, Li G et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Gut-Brain Axis-mediated Neurological Manifestations in Inflammatory Bowel Disease: Mechanisms and Disease Spectrum.

This review synthesized evidence on how the gut-brain axis contributes to neurological manifestations across the disease spectrum of inflammatory bowel disease (IBD), focusing on mechanisms such as microbiota imbalance, intestinal barrier disruption, immune activation/neuroinflammation, and neuroendocrine pathway abnormalities. It describes how impaired gut-brain communication can drive neuropsychiatric comorbidities (e.g., anxiety and depression) and outlines the interconnected biological pathways underlying these effects. The clinical significance is a framework for understanding and potentially targeting gut-brain mechanisms to treat or prevent neurological complications in IBD.

Sun B, Wang G, Li X et al. · Journal of neurogastroenterology and motility · (2026) · View on PubMed ↗ · Free PDF ↗

---

Obesity & Incretin-Based Metabolic Therapies

Early life sugar rationing and ageing related diseases, biological ageing and mortality.

Using the UK Biobank natural experiment of postwar sugar rationing, this study assessed whether early-life sugar rationing during the first 1,000 days influences biological ageing and mortality in 64,809 participants. Sugar rationing was associated with a lower incidence of hallmark-related diseases (HR ~0.91) and reduced all-cause mortality (HR ~0.81), with mediation analysis suggesting survival benefits were partly mediated by reduced incident hallmark-related disease. These findings provide human evidence that early-life nutritional restriction can shift long-term ageing-related risk and improve survival outcomes.

Zheng J, Zhou Z, Huang J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance.

This narrative review discussed the clinical significance of lean mass reduction observed during weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists, with attention to concerns about sarcopenia in older adults. The key finding is that decreases in lean mass measured by dual-energy X-ray absorptiometry (DXA) and similar body-composition tools do not necessarily translate into worse muscle quality, strength, or functional capacity. This is clinically important because it reframes how clinicians should interpret body-composition changes during incretin-based obesity and cardiometabolic therapy.

Moscucci F, Tocci G, Nardoianni G et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · (2026) · View on PubMed ↗ · Free PDF ↗

The Evolution of Medications for Obesity Management.

This narrative review examined the development of obesity medications, focusing on currently available agents and emerging therapies in the context of appetite and energy-balance mechanisms. It reports that the current generation of injectable incretin analogs—semaglutide and tirzepatide—achieve mean weight loss of about 15%–20% over roughly 12–18 months with improved safety/efficacy compared with earlier withdrawn drugs. These findings are clinically significant because they frame how modern incretin-based drugs can be used for long-term obesity management while highlighting the need for continued optimization of safety and effectiveness.

Gill J, Sumithran P · JGH open : an open access journal of gastroenterology and hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular Disease & Device/Interventional Therapies

Life’s Essential 10 and brain health: A prospective cohort study.

This prospective cohort study used UK Biobank participants aged 37–73 years (without baseline stroke or dementia) to develop and apply the Life’s Essential 10 (LE10) cardiovascular health framework and test how different CVH levels relate to life expectancy free of stroke and dementia. The key finding was that higher LE10-defined cardiovascular health was associated with greater stroke- and dementia-free life expectancy, supporting LE10 as a practical CVH metric for brain-health outcomes. This is clinically relevant because it links comprehensive cardiovascular risk assessment to long-term brain health in an aging population.

DU Y, Yang F, Ye Q et al. · Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · (2026) · View on PubMed ↗ · Free PDF ↗

Early mobilization trajectories during Impella 5.5 support and associated outcomes in patients with cardiogenic shock: A physiotherapy session-level analysis.

This physiotherapy session-level analysis studied early mobilization trajectories during Impella 5.5 support and their safety and prognostic associations in patients with cardiogenic shock. In consecutive ICU patients receiving Impella 5.5 (2022–2025), mobility was tracked using the ICU Mobility Scale (IMS) and related to adverse events and outcomes. The clinical significance is that it provides evidence to guide safe early rehabilitation practices during Impella 5.5–supported cardiogenic shock and to identify mobility patterns linked to prognosis.

Hamazaki N, Ikeda Y, Ichikawa T et al. · Heart & lung : the journal of critical care · (2026) · View on PubMed ↗

Interventional Treatment of Arterial Hypertension in The Modern Era: An Updated Review from the Young Investigator Group of the European Society of Hypertension.

This updated review from the European Society of Hypertension Young Investigator Group summarized modern interventional approaches for arterial hypertension, emphasizing strategies targeting autonomic and vascular regulation. It reports that renal artery denervation is the only intervention currently supported by guideline recommendations in selected patients, while baroreflex activation therapy and carotid body modulation show encouraging experimental results but remain under evaluation. The review is significant for guiding clinicians on which device-based therapies have the strongest evidence and regulatory support for hypertension management.

Şener YZ, Mancusi C, Ceasovschih A et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · (2026) · View on PubMed ↗ · Free PDF ↗

Prospective Evaluation of Quality-of-Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION-HF 12-Month Results.

This prospective, observational multi-center cohort study (EVOLUTION-HF) evaluated quality-of-life (QoL) improvement after initiating dapagliflozin in 257 consecutive patients with heart failure with reduced ejection fraction (HFrEF) in Greece. The key finding was that starting dapagliflozin was associated with QoL improvement over 12 months in this real-world HFrEF population. These results support the patient-centered benefit of SGLT2 inhibition with dapagliflozin alongside established clinical outcome effects in HFrEF.

Potoupni V, Boulmpou A, Maragkoudakis S et al. · Clinical cardiology · (2026) · View on PubMed ↗ · Free PDF ↗

Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.

This retrospective multicenter cohort study compared fourth-line glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus mineralocorticoid receptor antagonists (MRAs) in US patients with resistant hypertension and overweight or obesity. The key finding was the relative effectiveness of GLP-1RAs as an alternative to guideline-recommended MRAs for this population (with outcomes assessed in the cohort design). This is clinically significant because it informs evidence-based selection of later-line pharmacotherapy when MRAs are not used or are insufficient.

Tian Z, Willerding JM, Schmidt-Ott KM et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious Disease, Microbiology & Antimicrobial Safety

Differential impact of GVHD prophylaxis on CMV infection and survival outcomes after cord blood transplantation in the era of letermovir.

This retrospective study evaluated how graft-versus-host disease (GVHD) prophylaxis regimens—methotrexate (MTX) versus mycophenolate mofetil (MMF)—affect cytomegalovirus (CMV) infection and survival outcomes after cord blood transplantation (CBT) in the era of letermovir prophylaxis. In 2,849 CMV-seropositive adult CBT recipients, the analysis compared CMV outcomes and survival metrics with attention to whether letermovir was used, showing differential impacts of prophylaxis strategy on CMV infection and downstream survival. Clinically, it informs optimization of GVHD and infection prophylaxis to reduce nonrelapse mortality in CBT patients receiving modern CMV prevention.

Kawamura S, Akahoshi Y, Nakasone H et al. · Transplantation and cellular therapy · (2026) · View on PubMed ↗

Clinical and Microbiological Characteristics of Invasive Group A Streptococcus Infection: Four Case Series of Re-Emerging Pathogens.

This retrospective case series studied four intensive-care patients with invasive group A Streptococcus (iGAS) infection in Japan (March–May 2024), with genomic characterization focused on the M1UK lineage. The key finding was that M1UK-associated iGAS cases showed distinct clinical severity patterns consistent with re-emergence after the COVID-19 pandemic, prompting detailed clinical–microbiological–genomic correlation. These findings support improved molecular monitoring of iGAS (including M1UK) to better anticipate toxic shock syndrome risk and guide public-health and clinical preparedness.

Okahara S, Fukushima S, Hamaguchi Y et al. · Acute medicine & surgery · (2026) · View on PubMed ↗ · Free PDF ↗

---

Endocrine Disorders (Including Menopause & Cushing’s)

Non-hormonal strategies for menopausal health: the role of phytoestrogens.

This critical review evaluated non-hormonal menopausal health strategies, emphasizing phytoestrogens and their molecular mechanisms, bioavailability, and clinical applications. It finds that phytoestrogens may help mitigate risks such as osteoporosis, cardiovascular dysfunction, neuroprotection, and metabolic regulation, but clinical outcomes across studies are inconsistent and safety/standardization issues remain. The significance is that phytoestrogens are promising alternatives to hormone therapy, yet require better evidence and standardized formulations to guide clinical use.

Harahap IA, Weber D, Grune T · Critical reviews in food science and nutrition · (2026) · View on PubMed ↗ · Free PDF ↗

Approach to the Patient: Diagnosis and Management of Cushing’s Syndrome in the Elderly - How Different Is It?

This review article assessed how diagnosis and management of Cushing’s syndrome differ in elderly patients compared with younger adults. It finds that while diagnostic tests are largely the same, older adults often have a higher clinical threshold for testing, different interpretation of biochemistry, and different therapeutic endpoints because they may present atypically (e.g., diabetes/hypertension, falls, rapid bone loss, proximal weakness, venous thromboembolism, cognitive decline, or adrenal incidentaloma). This is clinically significant because it highlights the dual risk of missing true hypercortisolism versus overdiagnosing mild abnormalities in an age-related context.

Liu Y, Yi L, Tan H · The Journal of clinical endocrinology and metabolism · (2026) · View on PubMed ↗

---

---

Generated automatically on September 08, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.